New York City has emerged as a top-tier research hub, with world-class universities, a rapidly growing life sciences ecosystem, and unmatched access to capital and corporate partners. Melan works with NYC’s research institutions, corporate R&D teams, and foundations to structure the partnerships that drive discovery.
The New York City Research Partnership Landscape
New York’s research enterprise is anchored by Columbia University, New York University, Weill Cornell Medicine, The Rockefeller University, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, and Cold Spring Harbor Laboratory. These institutions attract over $2 billion in annual NIH funding and produce a steady stream of biomedical and AI research breakthroughs.
The corporate R&D presence is expanding rapidly. Google operates a significant AI research office in NYC. Pfizer, Bristol Myers Squibb, and Regeneron maintain deep research operations. The New York Genome Center and the CZI Biohub NY represent a new wave of collaborative research infrastructure. The city’s venture capital ecosystem — the second largest in the US — actively funds university spinouts and corporate-academic partnerships.
New York’s complexity comes from scale — dozens of major research institutions within a single metro area, each with its own TTO processes, IP policies, and partnership models. Melan navigates this complexity to find the right match.
What Melan Does for Teams in New York
Melan connects NYC’s research institutions with corporate partners and helps companies navigate the city’s dense and fragmented research landscape.
For corporate R&D teams: We map New York’s research ecosystem to identify the institutions and investigators aligned with your R&D priorities — from Columbia’s strength in AI and materials science to Memorial Sloan Kettering’s leadership in oncology research. We structure partnerships that match your commercial timeline with academic research rigor.
For NYC universities and medical centers: We help TTOs identify corporate partners who can scale their discoveries, negotiate licensing terms that reflect the commercial value of the technology, and structure sponsored research agreements that protect academic freedom.
For venture firms and startups: We help portfolio companies establish academic collaborations that validate their technology platform and generate the data needed for regulatory milestones and Series A/B financing.
FAQ
How does Melan help companies partner with Columbia or NYU?
We map the specific labs and PIs whose research aligns with your priorities, then approach the TTO with a pre-structured partnership framework — IP terms, funding model, milestones, and governance — that accelerates the negotiation process.
What makes NYC unique for research partnerships?
No other city combines elite biomedical research, AI and data science strength, and deep capital markets in a single geography. This creates partnership opportunities that don’t exist elsewhere — and a complexity that requires experienced navigation.
Does Melan work with NYC biotech and pharma companies?
Yes. We work with Pfizer, Bristol Myers Squibb, Regeneron, and emerging biotechs to identify academic partners across Columbia, Weill Cornell, Mount Sinai, and Memorial Sloan Kettering.
How do I start a research partnership in New York?
Contact Melan at themelan.com/contact-us. We discuss your R&D priorities and map the NYC research ecosystem to identify the right collaborators for your goals.
Ready to form a research partnership in New York?
Melan helps corporate R&D teams, universities, and medical centers across New York City structure successful research collaborations.
